Agios Pharmaceuticals (NASDAQ:AGIO) Releases Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Agios Pharmaceuticals (NASDAQ:AGIO) released its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.65) by ($0.04), FiscalAI reports. The company had revenue of $44.75 million during the quarter, compared to the consensus estimate of $26.39 million. Agios Pharmaceuticals had a negative net margin of 418.24% and a negative return on equity of 34.40%.

Here are the key takeaways from Agios Pharmaceuticals’ conference call:

• Mitapivat revenue reached $44.7 million in Q2, including $40.9 million in the U.S., while AQVESME generated 442 cumulative prescriptions from REMS-certified physicians. Payer coverage for U.S. thalassemia patients reached approximately 75%.
• The FDA accepted mitapivat’s sickle cell disease supplemental application for priority review with a November 1, 2026 PDUFA date; Agios is preparing for a potential launch, though the indication is not expected to materially contribute to 2026 revenue.
• Thalassemia launch dynamics are shifting toward a broader non-transfusion-dependent population, which may lengthen treatment initiation to the expected 10–12 weeks. Management will evaluate six-month patient benefit and persistence in the second half and plans to stop reporting REMS prescription counts after Q3 in favor of revenue metrics.
• Agios expanded its rare hematology pipeline by licensing cevidoplenib, a selective oral Syk inhibitor for immune thrombocytopenia, and plans to advance AG-236 into a seamless Phase II/III polycythemia vera program in the second half of 2026.
• The company ended the quarter with approximately $1 billion in cash and marketable securities, but operating expenses increased as commercial investment expanded; full-year operating expenses are expected to remain roughly flat versus 2025 excluding the $25 million cevidoplenib upfront payment.

Agios Pharmaceuticals Stock Down 8.3%

Agios Pharmaceuticals stock opened at $30.02 on Friday. Agios Pharmaceuticals has a twelve month low of $22.24 and a twelve month high of $46.00. The firm has a 50 day moving average price of $34.48 and a 200-day moving average price of $30.88. The company has a market capitalization of $1.79 billion, a P/E ratio of -4.28 and a beta of 0.54.

Institutional Trading of Agios Pharmaceuticals

A number of institutional investors have recently modified their holdings of AGIO. Creative Planning boosted its stake in shares of Agios Pharmaceuticals by 2.2% in the 3rd quarter. Creative Planning now owns 13,119 shares of the biopharmaceutical company’s stock valued at $527,000 after purchasing an additional 280 shares in the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Agios Pharmaceuticals by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 132,083 shares of the biopharmaceutical company’s stock valued at $4,393,000 after acquiring an additional 512 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of Agios Pharmaceuticals by 3.4% in the third quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock valued at $796,000 after acquiring an additional 662 shares during the period. California State Teachers Retirement System raised its stake in shares of Agios Pharmaceuticals by 1.4% during the second quarter. California State Teachers Retirement System now owns 47,659 shares of the biopharmaceutical company’s stock valued at $1,585,000 after acquiring an additional 671 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Agios Pharmaceuticals by 8.6% during the second quarter. Russell Investments Group Ltd. now owns 9,292 shares of the biopharmaceutical company’s stock valued at $309,000 after acquiring an additional 734 shares during the last quarter.

Analysts Set New Price Targets

A number of analysts recently commented on AGIO shares. Citigroup boosted their target price on Agios Pharmaceuticals from $46.00 to $52.00 and gave the company a “buy” rating in a research report on Friday. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Truist Financial dropped their price objective on shares of Agios Pharmaceuticals from $41.00 to $39.00 and set a “buy” rating on the stock in a research note on Friday. Royal Bank Of Canada boosted their target price on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Finally, Bank of America lifted their price target on Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $40.88.

Agios Pharmaceuticals News Summary

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: Second-quarter revenue from mitapivat products Pyrukynd and Aqvesme rose to $44.7 million from $12.5 million a year earlier, helped by Aqvesme’s U.S. launch in thalassemia. The company reported 442 cumulative prescriptions as of June 30. Agios second-quarter financial results
• Positive Sentiment: Agios reported a narrower quarterly loss than the Zacks consensus estimate, while management highlighted continued development of its hematology pipeline. The company also has $964.8 million in cash, cash equivalents and marketable securities to fund commercialization and research programs. Agios Q2 earnings report
• Positive Sentiment: The FDA granted priority review to mitapivat’s supplemental application in sickle cell disease, with a November 1, 2026 decision date. Approval could expand the drug’s addressable market. Agios also expects $45 million to $50 million in 2026 revenue from pyruvate kinase deficiency. Agios revenue outlook and sickle cell review
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $55 price objective while slightly raising its long-term 2030 EPS forecast. The forecast change supports the longer-term outlook but has limited immediate impact. Agios analyst estimates
• Negative Sentiment: Agios remains deeply unprofitable. Its reported quarterly loss of $1.69 per share was slightly worse than one analyst consensus estimate of $1.65, underscoring continued earnings risk despite revenue growth. Agios earnings results
• Negative Sentiment: Truist lowered its price target from $41 to $39, although it retained a Buy rating. Separately, Pomerantz announced an investigation into potential investor claims, creating an additional headline and legal overhang. Truist price target update

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.